Healthcare Stocks Alert: Carbylan Therapeutics Inc (CBYL), Tetraphase Pharmaceuticals Inc (TTPH)


Carbylan Therapeutics Inc (NASDAQ:CBYL):

Stock’s Trading Stats:

Carbylan Therapeutics Inc (NASDAQ:CBYL) surged 30.77% yesterday and closed at $0.819. The company’s market capitalization is at $21.78 Million with an average trading volume of 410,371.00. The total number of Outstanding Shares Held by the company are 26.33 Million.

Recent Press Release:

Carbylan Therapeutics, Inc. (CBYL) on April 15, 2016 declared that it has suspended further clinical development of Hydros-TA and that it is actively pursuing a planned transaction, counting a merger or acquisition of the company. As formerly declared, Carbylan has engaged Wedbush PacGrow to act as its planned financial advisor for this process.

In conjunction with the plan to pursue a planned transaction, Carbylan also declared an immediate reduction in its workforce of 14 employees of its current 17 employees in order to preserve capital and further streamline the Company’s operations in preparation for a potential planned transaction.

Carbylan presently projects that it will have about $25-$30 million of net cash accessible for the potential planned transaction. This projection is based on the Company’s current expectations and assumptions, counting the consummation of a transaction by the end of the third quarter of 2016, and the actual amount of net cash accessible could differ materially from the Company’s current estimate.

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH):

Stock’s Trading Stats:

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) closed at $5.85 yesterday by showing an increase of 5.60%. The total number of outstanding shares held by the company are 36.60 Million with the total market capitalization of $216.85 Million. The number of shares traded on the last trading session are 694,464.00.

Recent Press Release:

Tetraphase Pharmaceuticals, Inc. (TTPH) on April 7, 2016 declared five data presentations at the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place April 9-12 in Amsterdam, Netherlands.  Presentations will comprise information about the company’s lead drug candidate, eravacycline, in addition to data from its preclinical TP-6076 program.

Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, counting those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase’s pipeline comprises its late-stage broad-spectrum antibiotic, eravacycline, in addition to two additional antibiotic candidates, TP-271 and TP-6076. Please visit for more company information.